ImmuCell (NASDAQ: ICCC) extends $1M Maine Community Bank credit line to 2026

Rhea-AI Filing Summary

ImmuCell Corporation entered into an Allonge to and Amendment of its existing line of credit with Maine Community Bank. This agreement extends the Company’s $1 million line of credit through September 11, 2026, allowing continued access to this borrowing capacity.

Borrowings under the line of credit will bear interest at a variable rate equal to the National Prime Rate per annum. The extension represents an ongoing banking relationship rather than a new borrowing and is documented as a material definitive agreement and direct financial obligation.

8-K Event Classification

3 items: 1.01, 2.03, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0000811641 0000811641 2025-08-20 2025-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 20, 2025

ImmuCell Corporation

(Exact name of registrant as specified in its charter)

DE		001-12934		01-0382980
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

56 Evergreen Drive Portland, Maine		04103
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 207-878-2770

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 par value per share		ICCC		The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement

On August 20, 2025, ImmuCell Corporation (the “Company”) entered into an Allonge to and Amendment of Line of Credit (the “Allonge”) between the Company and Maine Community Bank (MCB) pursuant to which the Company’s $1 million line of credit with MCB was extended through September 11, 2026. Interest on borrowings against the Line of Credit is variable at the National Prime Rate per annum.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.

Item 9.01.  Exhibits.

(d) Exhibits.

10.1		Allonge to and Amendment of Line of Credit Loan between the Company and Maine Community Bank dated August 20, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUCELL CORPORATION
Date: August 25, 2025	By:	/s/ Michael F. Brigham
		Michael F. Brigham
		President and Chief Executive Officer
Date: August 25, 2025	By:	/s/ Timothy C. Fiori
		Timothy C. Fiori
		Chief Financial Officer

2

Exhibit Index

Exhibit No.		Description
10.1		Allonge to and Amendment of Line of Credit Loan between the Company and Maine Community Bank dated August 20, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

3

FAQ

What financing agreement did ImmuCell (ICCC) enter on August 20, 2025?

ImmuCell entered an Allonge and Amendment to its line of credit with Maine Community Bank, formally extending an existing $1 million revolving credit facility and updating terms as a material definitive agreement under the Securities Exchange Act.

What is the size of ImmuCell’s line of credit with Maine Community Bank?

ImmuCell’s line of credit with Maine Community Bank is for $1 million. The 8-K describes this facility as a continuing source of liquidity for the company, with the maturity date extended and interest charged at the variable National Prime Rate per annum.

Until when is ImmuCell’s $1 million credit line now extended?

The $1 million line of credit is extended through September 11, 2026. This new maturity date replaces the prior expiration and keeps the facility available for borrowings over that period, subject to the other terms agreed with Maine Community Bank.

What interest rate applies to ImmuCell’s line of credit with Maine Community Bank?

Borrowings under the line of credit accrue interest at a variable rate equal to the National Prime Rate per annum. This means the cost of the debt will move in line with changes to the widely referenced National Prime Rate benchmark.

Which 8-K items did ImmuCell (ICCC) report in this filing?

ImmuCell reported under Item 1.01 for entry into a material definitive agreement and Item 2.03 for creation of a direct financial obligation. The filing cross-references the credit line amendment details between these two disclosure items.

Who are the counterparties to ImmuCell’s amended line of credit?

The amended line of credit is between ImmuCell Corporation and Maine Community Bank. The Allonge and Amendment formally documents their continued lending relationship, extending the $1 million revolving facility and maintaining prime-based interest terms.